hero image

Biogen Idec Announces March 25 Webcast of Research & Development Day

March 18, 2009 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) announced today that it will hold its 2009 R&D Day on Wednesday, March 25, 2009 from 1 PM ET to 5 PM ET. Dr. Cecil Pickett, Biogen Idec's President of Research & Development, along with members of the Company's R&D leadership team will provide a detailed review of the Company's pipeline programs.

Media, investors and the general public can access the live event by visiting the "Investor" section of the Biogen Idec web site, investor.biogenidec.com. Audio and slide presentations will be available through the web site. An archived version of the webcast will be available for 30 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.



Biogen Idec
Investor Relations
Rob Jacobson, 617-679-2812

September 29, 2023
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept.

September 26, 2023
Biogen Completes Acquisition of Reata Pharmaceuticals

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition